BridgeBio Oncology Therapeutics, Inc.
BBOT
$6.76
-$2.11-23.76%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -34.08% | -8.53% | 13.32% | -57.40% | -28.93% |
| Total Depreciation and Amortization | 2.69% | -4.12% | 7.18% | 0.00% | 235.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 101.19% | 32.90% | -67.61% | 1,714.81% | -48.52% |
| Change in Net Operating Assets | 93.25% | 134.00% | -192.84% | 56.16% | 206.93% |
| Cash from Operations | -23.51% | 14.96% | -46.81% | -23.50% | -18.85% |
| Capital Expenditure | -95.83% | 67.12% | 47.86% | 39.39% | -42.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 116.04% | -3,740.55% | -80.74% | 312.31% | -36.45% |
| Cash from Investing | 116.02% | -3,775.08% | -80.85% | 320.74% | -37.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -91.11% | 824.44% | -99.99% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 80.82% | 92.13% | -145.59% | -708.42% |
| Cash from Financing | -87.46% | 150.34% | -100.16% | 1,827.81% | 4,792.08% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.44% | -815.81% | -109.29% | 7,014.73% | 214.39% |